Sei Yonezawa, Ph.D.

Institution: Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka
Position: Assistant Professor
E-Mail: yonezawa@u-shizuoka-ken.ac.jp
Address: 52-1 Yada, Suruga-ward, Shizuoka-city, Shizuoka 422-8526, Japan
Tel:+81 54-264-5700, FAX: +81 54-264-5705

Education:

Apr. 2004 to Mar. 2007 Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan (Ph.D.)

Apr. 2002 to Mar. 2004 Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan (M. Sc.)

Apr. 1998 to Mar. 2002 School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan (B. Sc.)

Employment

Jan. 2019 to present	University of Shizuoka, School of Pharmaceutical Science, Assistant Professor
Apr. 2009 to Dec. 2018	Iwate Medical University, School of Pharmacy, Research Assistant Professor
Apr. 2008 to Mar. 2009	Iwate Medical University, School of Pharmacy, Teaching Assistant
Apr. 2007 to Mar. 2008	Research Institute International Medical Center of Japan, Postdoctoral fellow

Menbership:

The Pharmaceutical Society of Japan

The Japanese Conference on the Biochemistry of Lipids

Awards:

Controlled Release Society travel award (Jul. 2003)

Journal articles

1) Yonezawa S, Abe M, Kawasaki Y, Natori Y, Sugiyama A: Each liver X receptor (LXR) type has a different purpose in different situations. Biochem. Biophys. Res. Commun. 508, 92-96 (2019)
2) Ogasawara N, Kudo T, Sato M, Kawasaki Y, Yonezawa S, Takahashi S, Miyagi Y, Natori Y, Sugiyama A: Reduction of Membrane Protein CRIM1 Decreases E-Cadherin and Increases Claudin-1 and MMPs, Enhancing the Migration and Invasion of Renal Carcinoma Cells. Biol. Pharm. Bull. 41,604-611 (2018)
3) Shimizu K, Miyauchi H, Urakami T, Yamamura-Ichikawa K, Yonezawa S, Asai T, Oku N: Specific delivery of an immunosuppressive drug to splenic B cells by antigen-modified liposomes and its anti-allergic effect. J. Drug Target. 1-29 (2016)
4) Kawasaki Y, Yokobayashi E, Sakamoto K, Tenma E, Takaki H, Chiba Y, Otashiro T, Ishihara M, Yonezawa S, Sugiyama A, Natori Y: Angiostatin prevents IL-1β-induced down-regulation of eNOS expression by inhibiting the NF-κB cascade. J. Pharmacol Sci. 129, 200-2004 (2015)

5) Ichikawa K, Asai T, Shimizu K, Yonezawa S, Urakami T, Miyauchi H, Kawashima H, Ishida T, Kiwada H, Oku N: Suppression of immune response by antigen-modified liposomes encapsulating model agents: A novel strategy for the treatment of allergy. J. Control. Release 167, 284-289 (2013)
6) Asai T, Suzuki Y, Matsushita S, Yonezawa S, Yokota J, Katanasaka Y, Ishida T, Dewa T, Kiwada H, Nango M, Oku N: Disappearance of the angiogenic potential of endothelial cells caused by Argonaute2 knockdown. Biochem. Biophys. Res. Commun. 368, 243-248 (2008)
7) Ichikawa K, Urakami T, Yonezawa S, Miyauchi H, Shimizu K, Asai T, Oku N: Enhanced desensitization efficacy by liposomal conjugation of a specific antigen. Int. J. Pharm. 336, 391-395 (2007)
8) Yonezawa S, Asai T, Oku N: Effective tumor regression by anti-neovascular therapy in hypovascular orthotopic pancreatic tumor model. J. Control. Release 118, 303-309 (2007)
9) Siripong P, Yahuafai J, Shimizu K, Ichikawa K, Yonezawa S, Asai T, Kanokmedakul K, Ruchirawat S, Oku N: Antitumor activity of liposomal naphthoquinone esters isolated from thai medicinal plant: Rhinacanthus nasutus Kurz. Biol. Pharm. Bull. 29, 2279-2283 (2006)
10) Siripong P, Yahuafai J, Shimizu K, Ichikawa K, Yonezawa S, Asai T, Kanokmedakul K, Ruchirawat S, Oku N: Induction of apoptosis in tumor cells by three naphthoquinone esters isolated from thai medicinal plant: Rhinacanthus nasutus KURZ. Biol. Pharm. Bull. 29, 2070-2076 (2006)
11) Maeda N, Miyazawa S, Shimizu K, Asai T, Yonezawa S, Kitazawa S, Namba Y, Tsukada H, Oku N: Enhancement of anticancer activity in antineovascular therapy is based on the intratumoral distribution of the active targeting carrier for anticancer drugs. Biol. Pharm. Bull. 29, 1936-1940 (2006)
12) Ichikawa K, Hikita T, Maeda N, Yonezawa S, Takeuchi Y, Asai T, Namba Y, Oku N: Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels. Biochim. Biophys. Acta 1669, 69-74 (2005)
13) Takeuchi Y, Ichikawa K, Yonezawa S, Kurohane K, Koishi T, Nango M, Namba Y, Oku N: Intracellular target for photosensitization in cancer antiangiogenic photodynamic therapy mediated by polycation liposome. J. Control. Release. 97, 231-240 (2004)
14) Shigeta Y, Imanaka H, Yonezawa S, Oku N, Baba N, Makino T: Suppressed permeation of linoleic acid in a liposomal formulation through reconstructed skin tissue. Biol. Pharm. Bull. 27, 879-882 (2004)
15) Tamura M, Unno K, Yonezawa S, Hattori K, Nakashima E, Tsukada H, Nakajima M, Oku N: In vivo trafficking of endothelial progenitor cells their possible involvement in the tumor neovascularization. Life Sci. 75, 575-584 (2004)
16) Ichikawa K, Takeuchi Y, Yonezawa S, Hikita T, Kurohane K, Namba Y, Oku N: Antiangiogenic photodynamic therapy (PDT) using Visudyne causes effective suppression of tumor growth. Cancer Lett. 205, 39-48 (2004)
17) Takeuchi Y, Kurohane K, Ichikawa K, Yonezawa S, Ori H, Koishi T, Nango M, Oku N: Polycation liposome enhances the endocytic uptake of photosensitizer into cells in the presence of serum. Bioconjug. Chem. 14, 790-796 (2003)
18) Takeuchi Y, Kurohane K, Ichikawa K, Yonezawa S, Nango M, Oku N: Induction of intensive tumor suppression by antiangiogenic photodynamic therapy using polycation-modified liposomal photosensitizer. Cancer. 97, 2027-2034 (2003)

Book

Yonezawa S, Asai T, Oku N: Dosal air sac model. Angiogenesis assays, 229-238 John Wiley & Sons, Ltd (2007)